BTC $82,979.42 +1.13%
ETH $2,458.02 +2.07%
BNB $741.94 +1.59%
XRP $1.34 +2.38%
SOL $106.91 +1.63%
TRX $0.3310 -0.01%
DOGE $0.0818 +2.57%
ADA $0.2239 +2.45%
BCH $283.36 +1.36%
LINK $12.33 +2.40%
HYPE $81.17 +2.54%
AAVE $156.13 +4.29%
SUI $1.03 +3.23%
XLM $0.1819 +2.43%
ZEC $1,271.83 +9.85%
AAPL $339.07 -1.27%
AMZN $264.27 +0.38%
GOOGL $341.48 -0.99%
MSFT $531.35 -0.41%
META $696.01 -1.60%
NVDA $221.25 +1.62%
TSLA $379.57 +2.94%
SNDK $1,411.65 +2.21%
INTC $95.49 +3.11%
SPCX $158.03 +6.03%
MU $921.78 +1.39%
AMD $549.54 +1.62%
BTC $82,979.42 +1.13%
ETH $2,458.02 +2.07%
BNB $741.94 +1.59%
XRP $1.34 +2.38%
SOL $106.91 +1.63%
TRX $0.3310 -0.01%
DOGE $0.0818 +2.57%
ADA $0.2239 +2.45%
BCH $283.36 +1.36%
LINK $12.33 +2.40%
HYPE $81.17 +2.54%
AAVE $156.13 +4.29%
SUI $1.03 +3.23%
XLM $0.1819 +2.43%
ZEC $1,271.83 +9.85%
AAPL $339.07 -1.27%
AMZN $264.27 +0.38%
GOOGL $341.48 -0.99%
MSFT $531.35 -0.41%
META $696.01 -1.60%
NVDA $221.25 +1.62%
TSLA $379.57 +2.94%
SNDK $1,411.65 +2.21%
INTC $95.49 +3.11%
SPCX $158.03 +6.03%
MU $921.78 +1.39%
AMD $549.54 +1.62%

m

All
Article
Flash

first_img OpenAI acquires Orchestra Bio, AI entities take over drug development

OpenAI announced the acquisition of San Francisco startup Orchestra Bio, which has developed AI agents to help pharmaceutical companies track the progress of drug development projects. Orchestra's team and platform will be integrated into OpenAI's life sciences product line Rosalind, aimed at biologists and chemists, with the transaction amount undisclosed. Orchestra was founded in the fall of 2022, with seed funding from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC, raising a total of approximately $20 million.According to OpenAI, a new drug can take up to 15 years from initial conception to approval in the United States, and the cost of bringing a single approved drug to market can exceed $2.6 billion, with less than 10% of candidate drugs entering human trials ultimately reaching the market. Orchestra's AI agents can automatically monitor tasks and flag issues, analyze how setbacks like production batch failures affect the overall development project, compile relevant information, and compare response strategies, ultimately allowing scientists and project leaders to make decisions.This acquisition follows competitor Anthropic's acquisition of Coefficient Bio for approximately $400 million in April, reflecting the competition among AI labs for new drug development workflows. In April, OpenAI launched the model GPT-Rosalind specifically designed for biology and drug discovery, available only to vetted U.S. corporate clients such as Amgen and Moderna, with the accompanying product Rosalind Workbench connecting the model to research tools and data.

first_img NEAR has initiated voting to reduce the issuance rate to 1.6% over 24 months

The NEAR ecosystem governance proposal HSP-029 has entered the voting stage, proposing to gradually reduce the maximum annual issuance rate of NEAR tokens from 2.5% to 1.6%. This proposal was put forward by SVRN CEO Sal Ternullo, planning to linearly decrease by approximately 3.75 basis points per epoch over 24 months, while maintaining a 90/10 allocation ratio between stakers and the treasury. After the vote passes, there will be a 90-day grace period before the reduction officially begins.The proposal's calculations indicate that this plan is expected to reduce the issuance of approximately 11.8 million NEAR tokens over two years, with a cumulative reduction of about 66.1 million tokens over six years, equivalent to a 4.36% decrease in supply compared to the current situation. The annualized staking yield will gradually decrease from the current 5.268% to 3.372%. The author points out that this move aims to reduce the degree of dilution for non-staking holders and responds to discussions regarding the protocol's discretion risk following the withdrawal of the previous Sovereign Fund proposal.This proposal must go through a dual process to take effect: after passing the House of Stake vote, validators must also independently adopt it through the standard protocol upgrade process. The proposal cites Solana's SGP-0002, which was passed in August 2026 with a staking weight approval of 67.001% for a similar issuance reduction, as a precedent. Currently, the NEAR network has a total of 406 active validators, with a staking rate of 42.71%.
app_icon
ChainCatcher Building the Web3 world with innovations.